Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC

• Main Authors: Viviana Frantellizzi, Julia Lazri, Mariano Pontico, Arianna Pani, Giuseppe De Vincentis
• Format: Article
• Language: English
• Published: PAGEPress Publications 2020-10-01
• Series: Archivio Italiano di Urologia e Andrologia
• Subjects: Radium-223 dichloride; Bone pain; Palliative treatment; mCRPC
• Online Access: https://www.pagepressjournals.org/index.php/aiua/article/view/8854
• ISSN: 1124-3562; 2282-4197

Objective. Bone secondary localizations from metastatic castration-resistant prostate cancer are associated with an increase in mortality and a reduction in the patient’s quality of life. Radium-223 is a targeted alpha-therapy approved for the treatment of mCRPC (metastatic castration resistant prostate cancer) patients with symptomatic bone metastases. To our knowledge, no previous study has been performed assessing the bone pain palliation outcomes following Radium-223 therapy. Materials and Methods. A mCRPC patient with symptomatic bone localizations and relevant bone pain symptoms has been subjected to Radium-223 treatment. Pain was assessed over time from the first administration of Radium-223 to follow-up. Results. After Radium-223 treatment, patient showed a significant BPI (Brief Pain Inventory) decline from 7 to 4 and a concomitant partial regression of multiple bone hot spots in the bone scan exam. Three months after the last infusion of Radium-223, further BPI decline (from 4 to 2) with bone scan depicting stable disease was observed. However, after 6 months from Radium-223 treatment end, BPI increased from 2 to 10. Conclusions. Taking into account the effectiveness on bone pain relief and the low toxicity profile showed by Radium-223 treatment, we encourage further analysis on large cohort to investigate the clinical outcome after Radium-223 treatment, in terms of bone pain palliation, together with the possibility of Radium-223 re-treatment in selected patients..